FDA Recalls Perphenazine Tablets Due to Potential Label Mixup
Aidapak Services is recalling 16 mg Perphenazine tablets because they may have been mislabeled as other prescription drugs.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric, particularly given the risk of administering the wrong medication.
Plain-English summary
Aidapak Services, LLC is recalling 1,200 tablets of Perphenazine, 16 mg, NDC 00781104901. The recall was initiated because the product may have been mislabeled as other prescription medications, including Lithium Carbonate ER, Raltegravir, or Venlafaxine HCl.
The affected repacked drugs were distributed in Arizona, California, Oregon, and Washington. Specific pedigree codes and expiration dates for the recalled Perphenazine tablets are listed in the agency's official notice.
Consumers and healthcare providers should check their inventory for the specific NDC and pedigree codes listed in the FDA recall notice. If the product is found, it should be returned to the distributor or disposed of according to local regulations. Patients should consult their healthcare provider if they have questions about their medication.
The recalled product
- Product
- PERPHENAZINE, Tablet, 16 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781104901.
- Manufacturer
- Aidapak Services, LLC
- Category
- Drug — Prescription Medication
- Affected units
- 1,200
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- PERPHENAZINE
- Tablet
- 16 mg has the following codes: Pedigree: AD21790_31
- EXP: 5/1/2014
- Pedigree: W002731
- EXP: 6/6/2014
- Pedigree: W003682
- EXP: 6/25/2014
- Pedigree: AD73525_22
- EXP: 5/30/2014
- Pedigree: W003328
- EXP: 6/19/2014.
Distribution
Part of a larger recall action
This product is one of 265 recalled by Aidapak Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 265 products in this recall →Related recalls
Same manufacturer · Aidapak Services, LLC
See all →- ModerateAidapak Recalls Sennosides Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateLevothyroxine Sodium Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Mislabeled Pantoprazole Sodium DR Tablets
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nifedipine ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateSimvastatin Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-29
Same hazard · mis labeling
See all →- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-10-14
- HighJ K Patisserie Chocolate Chip Cookies Recalled for Undeclared Soy
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- LowMindray ePM Series Patient Monitor Manuals Recalled for Alarm Clarification
FDA (Devices) · 2026-10-14
Similar recalls
- HighAidapak Recalls Mirtazapine Tablets Due to Potential Labeling Mixup
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls Phytonadione Tablets Due to Potential Labeling Mixup
FDA (Drugs) · 2014-01-22
- SevereAidapak Recalls Guanfacine Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- ModerateFDA Recalls Tizanidine Tablets Due to Potential Labeling Mixup
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls Phytonadione Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls Diphenhydramine Tablets Due to Potential Labeling Mixup
FDA (Drugs) · 2014-01-22